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Abstract:  
       The study aimed to prepare novel derivative of metformin similar to the work of the enzyme inhibitors DPP-
4 and so the need for new inhibitors may be a side effect with less addition to linking types of drugs have a 
stronger effect on patients with diabetes and to study the impact of this derivative inside the living cell has been 
prepared derived through interaction metformin with propargyl chloride. It was to make sure the chemical 
structure by using analytical and spectral methods (FT-IR, 1H-NMR, and 13C-NMR), and the results confirming 
the obtained structures,  then purified by column chromatography by using silica gel as stationary phase and 
methanol as a mobile phase. The study is derived on the impact of rabbits where they were taking the 40 rabbits 
with similar weights and were divided into four groups (10 rabbits per group) weredivided as follows, the first 
group G1 obtained as a control group, which did not gave any things. The second group G2 has injected by 
aloxane a concentration of 120 mg / kg using syringes medical capacity of 3 ml to inject rabbits in the vein ear 
and after two hours of injection they were given glucose solution of 10%, the confirmed they injured rabbits 
diabetes by measuring blood sugar to 10 rabbits have been selected randomly and then it was taken two sets of 
this group, the third group G3 were given a drug sitagliptin with concentration of 10 mg / kg, and the fourth 
group G4, were given the prepared derivative with concentration of 8 mg / kg for 3 days and pulled blood 
samples after the last dose on the third day. Serum used in determination of lipid profile,DPP-4 activity,alanine 
transaminase(ALT),Aspartate transaminase(AST) and insulin. Results of statistical analysis showed a significant 
decrease in the level of FBG and  DPP-4 activity  of  the prepared derivative, and also showed a decrease in the 
level of cholesterol, triglyceride, LDL and VLDL, while  results showed increase in HDL level in G4 comparing 
to G1. 
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Introduction 
       Diabetes is a major global disease that around 382 million people of the world’s population have diabetes 
mellitus in 2013 and by 2035, this will rise to 592 million[1]. Therapies targeting the incretin system are 
important for management of type 2 diabetes. Two principal incretin hormones—glucagon-like peptide-1 (GLP-
1) and glucose dependent insulinotropic polypeptide (GIP)—are rapidly released after meals. Both hormones 
augment glucose dependent insulin secretion; and GLP-1, but not GIP, also suppresses glucagon secretion, 
delays gastric emptying, and decreases food intake. GLP-1 and GIP are inactivated by the enzyme dipeptidyl 
peptidase-4 (DPP-4)[2]. Incretin-based therapies consist of two drug classes: GLP-1 receptor agonists, which 
have biological activity similar to GLP-1, but are resistant to DPP-4; and DPP-4 inhibitors, which prevent 
enzymatic inactivation of endogenous GLP-1 and GIP[3]. 
       The dipeptidyl peptidase (DPP)-4 inhibitors are a new class of anti hyperglycaemic agents which were 
developed for the treatment of type 2 diabetes by rational drug design, based on an understanding of the 
underlying mechanism of action and knowledge of the structure of the target enzyme[4]. As a therapeutic class, 
the DPP-4 inhibitors comprise a diverse group of compounds, which can be broadly divided into those that 
mimic the dipeptide structure of DPP-4 substrates and those which are non-peptido mimetic compounds such as 
sitagliptin (β-amino acid based)[5]. The DPP-4 enzyme has two binding pockets/sites (S1, and S2). The S1 
pocket consists of catalytic triad (Ser630, Asn710 and His740) and the S2 pocket involves key interactions with 
Glu205 and Glu206 dyad and Arg125. Later is a larger cavity surrounded by residues of Val207, Ser209, Arg358 
and Phe357 which makes S2 extensive subsite[6] 
 
Materials and Methods 
1-Organic part: 
Preparation of metformin derivative[7] 
In a round bottomed  flask(5gm, 0.03 mole) metformin and (1.2 gm, 0.03 mole)sodium hydroxide in (150 mL) 
methanol were added, stirred for 10 minutes, then 2.1 mL of propargyl chloride in 21 mL methanol was added to 
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the mixture drop wise, refluxed for 24 hours. The solvent evaporated under reduced pressure to result (6.2 gm, 
93.32%). The resulting purified by a column chromatography length of 70 cm and diameter of 2.5 cm, packing 
by silica gel (35-70) as a stationary phase and methanol as a mobile phase, the spot was followed by TLC. 
2-Biochemistry part 
       In this study, 40 rabbits has been obtained and divided in to four groups, (G1) control group, (G2) rabbits 
with  diabetic induced by 120mg/Kg  alloxane, (G3) rabbits with diabetic that adminstrated 10mg/Kg sitagliptin 
drug for 3 days and (G4) rabbits with diabetic that adminstrated  8mg/Kg of the prepared derivative for 3 days. 
Ten milliliters of fasting blood were collected from all subjects. The serum obtained used in determination of 
Dipeptidyl peptidase-4(DPP-4)  by ELISA, (US Biological Kit/ USA), depending on the competitive with 
antibodies of DPP-4 on wells of the plate and antibodies at horseradish peroxidase to linked with the DPP-4 
antigen in blood serum[8], fasting blood glucose(FBG)[9], Insulin by determined TOSOH instrument with 
special kit[10], alanine transaminase(ALT), Aspartate transaminase(AST)[11,12] and lipid profile(total 
cholesterol (Ch)[13], triglyceride(TG)[14],high density lipoprotein(HDL)[15],determined according to the 
standard procedures of the biochemistry laboratory of the hospital.and (VLDL-Ch),(LDL) concentrations were 





Results and Discussion: 
1-Organic part: 
 The synthesis of acetylinc derivative of metformen has been obtained by the reflux of metformine with 
propargyl chloride in methanol according to the reaction below: 
 
      The derivative was purified by a column chromatography(silica gel as stationary phase and methanol as a 
mobile phase) and follow up by TLC. The characterization of the acetylinc derivative was accomplished by 
measuring spectral data, FT-IR which showed the presence of the absorbance band at 3178 cm-1  for H acetylinic, 





VLDL-CH(mg/dL) = Triglyceride / 5 
LDL-Ch(mg/dL) = Total cholesterol-(HDL-Ch + VLDL-Ch) 
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Table(1): 1HNMR and 13CNMR of metformin derivative 
 
 
 A 66.10 – 73.20 A 2.65 – 2.70 
B 80.10 – 82.01 B 3.20 – 3.66 
C 33.30 – 36.09 C 5.00 – 5.02 
D 160.01 – 166.09 D 2.83 – 2.97 
E 37.80 – 38.60 E 4.70 – 4.74 
F 172.16 – 173.01 F 5.00 – 5.02 
    
    Figure (1,2 and 3) showsFTIR, 1H-NMR and  13CNMR spectrum  for the metformin derivative respectively.  
2-Biochemistry part 
       The results of DPP-4 at table (2), and figure(4) showed  significant decrease in the concentration of enzyme 
inG3and G4 compared with the G2, and the values were 55.32± 26.96, 31.64±12.65 and 137.65±30.90 Pg/mL 
respectively.Significant decrease found in G3 compared with G4, , Results also showed a significant decrease in 
the FBG level in G3 and G4 compared with the G2, and the values were 150.70± 11.96, 124.30± 25.88 and 
214.90± 27.67 mg/ dl respectively, which means that the effect of the prepared derivative record the strongest 
inhibitory effect than sitagliptin , Results showed a significant decrease in the insulin level in of G3 and G4 
compared with the G2, and the values were 9.48±1.48, 8.67±1.70 and 13.07±1.67 µU/mL respectively. The 
DPP-4 inhibition with sitagliptin improved the expression of GLP-1 and GLP-1R in pancreas. Since, GLP-1R 
stimulate the adenylyl cyclase pathway, and increase the insulin synthesis in langerhans islet[17][18], so 
sitagliptin can restore damaged pancreas[19]. The change in all hormones with respect to expression and blood 
glucose level indicate that sitagliptin may cause the regulation of hyperglycemia in type-2 diabetes[20]. 
       All these results confirm the novel ability of the prepared derivative in treating the hyperglycemic, and its 
results similar to the results of sitagliptin which mean that may be have similar properties.  
Figure(5) show the proposed designing model of the combination between the prepared derivative and the active 
site of DPP-4.  
      The results of table(3), and figure(6) shows inhibitory effect in G3 and G4 comparing with the injury group 
G2 in the liver enzymes AST and ALT, and the values were 52.500± 8.50, 50.700±12.18 and 76.700± 16.36 U/L 
for AST, 43.100± 8.87, 44.600±12.20 and 77.700±15.46 U/L for ALT respectively. 
 Table (4), and figure(7)  illustrates the comparing between the divided groups on lipid profile, data that indicate 
a significant decreases in the levels of cholesterol and  triglyceride in G3 and G4 comparing with G2, and the 
values were 144.08±18.78, 152.34±25.11 and 255.25±18.28 mg/dL for Ch, 154.70±30.38, 158.08±52.11 and 
299.92±28.73 for TG respectively. Furthermore, table (4) showed a significant increased in HDL-Ch in G3 and 
G4 comparing with G2, and the values were 31.20±3.61, 33.50±4.62 and 27.80±2.29 mg\dL respectively, and a 
significant decreases in LDL-Ch and VLDL-Ch between G3 and G4 comparing with G2, and the values were 
84.64±19.10, 88.05±20.22 and 136.66±20.8 mg/dL for LDL-Ch, and 30.94±6.07, 31.60±10.06 and 61.98±5.82 
mg/dL  respectively.  
       The level of free fatty acids in blood serum increase because of the low levels of glucose in diabetic 
patients,so the free fatty acids are catabolized In liver to result acetyl CoA, the excess of acetyl CoA is convert to 
cholesterol, triglyceride and ketone bodies and other lipoproteins like LDL and VLDL. The abnormally high 
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concentration of serum lipoprotein in the diabetic patients  may also be due to the increase in the mobilization of 
free fatty acids from the peripheral fat depots by glucagon in the absence of insulin [21].  
       Tables (5,6,7 and 8) shows Correlations between biochemical parameters for G1, G2, G3 and G4 
respectively. 
Conclusions  
Adding acetylinic terminal to metformin gives good results in lowering level of sugar. The prepared derivative 
reduce the concentration of DPP-4 more than sitagliptin at the same dose. The glucose level reduced to normal 
value when the rabbits with diabetic treated with the prepared derivative. The level of insulin back to the normal 
level when rabbits treated with the prepared derivative. Cholesterol, triglyceride and LDL-Ch beck to the normal 
value when treated with the prepared derivative. 
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Table (2): Mean ± SD of DPP-4, Glucose and Insulin for G1, G2,G3 and G4 
 
 
Table (3): Mean ± SD of AST and ALT for G1, G2,G3 and G4  
  







letters vertically means that there is significant difference between the groups, P≤0.05 
Difference letters vertically means that there is significant difference between the groups, P≤0.05 
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ALT U/L -0.491         
AST U/L -0.125 0.020        
Ch. mg/dL -0.073 -0.339 -0.121       
HDL mg/dL 0.024 0.092 -0.529 -0.273      
TG mg/dL -0.434 0.013 0.079 -0.141 -0.137-     
LDL mg/dL -0.128 -0.341 0.222 0.828** -0.635* -0.231    
VLDL mg/dL -0.710* 0.360 -0.025 -0.518 0.137 0.605 -0.389   
Glu. mg/dL 0.492 -0.189 0.376 0.234 -0.293 -0.305 0.289 -0.659*  
Insulin µU/mL -0.038 0.516 0.145 0.296 -0.448 -0.318 0.373 -0.382 0.401 
 
*. Correlation is significant at the 0.05 level (2-tailed) 
**. Correlation is significant at the 0.01 level (2-tailed) 
   
Difference letters vertically means that there is significant difference between the groups, P≤0.05 
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ALT U/L -0.491 
        
AST U/L -0.125 0.020 
       
Ch.  mg/dL -0.073 -0.339 -0.121 
      
HDL mg/dL 0.024 0.092 -0.529 -0.273 
     
TG mg/dL -0.434 0.013 0.079 -0.141 -0.137- 
    
LDL mg/dL -0.128 -0.341 0.222 0.828** -0.635* -0.231 
   
VLDLmg/dL -0.710* 0.360 -0.025 -0.518 0.137 0.605 -0.389 
  
Glu. mg/dL 0.492 -0.189 0.376 0.234 -0.293 -0.305 0.289 -0.659* 
 
Insulin µU/mL -0.038 0.516 0.145 0.296 -0.448 -0.318 0.373 -0.382 0.401 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 

















ALT U/L 0.228         
AST U/L 0.703* -0.094        
Ch. mg/dL -0.607 0.085 0.495       
HDL mg/dL 0.822** -0.264 -0.792** -0.698*      
TG mg/dL 0.346 0.551 -0.186 0.089 0.016     
LDL mg/dL -0.657* -0.163 0.414 0.857** -0.548 -0.012    
VLDL 
mg/dL 
0.114 0.515 -0.156 -0.199 -0.118 0.294 -0.513 
  
Glu.  mg/dL 0.554 0.055 -0.693* -0.548 0.644* -0.223- -0.345 -0.078  
Insulin 
µU/mL 
0.037 -0.088 -0.113 -0.524 0.201 -0.429 -0.188 -0.138 0.711* 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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ALT U/L 0.045         
AST U/L -0.439 0.629        
Ch. mg/dL 0.018 -0.339 -0.340       
HDL mg/dL 0.126 -0.522 -0.589 0.361      
TG mg/dL 0.176 0.142 0.364 0.448 -0.147     
LDL mg/dL -0.158 -0.400 -0.474 0.900** 0.359 0.044    
VLDLmg/dL 0.176 0.143 0.364 0.447 -0.148 1.000** 0.043   
Glu.  mg/dL -0.126 0.627 0.165 0.342 -0.106 0.222 0.341 0.223  
Insulin µU/mL 0.354 -0.221 -0.279 0.439 0.451 0.548 0.173 0.548 0.106 
 
*. Correlation is significant at the 0.05 level (2-tailed). 





Figure (1) Shown FTIR spectrum for metformin derivative 
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 Figure(2)Shown Spectrum 1HNMR for metformin derivative  
 
 Figure (3) Shown spectrum13CNMR for metformin derivative 
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Figure(5) The proposed interaction between the prepared derivative and the active site of DPP-4 
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Figure (7): Difference between the groups at Ch., HDL-Ch., TG, LDL-Ch. and VLDL-Ch 
 
 
 
 
 
